Developing Countries Vaccine Manufacturers Network

What Developing Countries Vaccine Manufacturers Network does

Developing Countries Vaccine Manufacturers Network (DCVMN), legally DCVMN International, is a voluntary public health-driven alliance founded in 2000 and headquartered in Geneva, Switzerland. The organization comprises 48 public and private vaccine manufacturers across 17 developing countries spanning all six WHO regions, functioning as a collaborative platform for regulatory harmonization, technology transfer, South-South cooperation, and advocacy for vaccine equity. DCVMN does not manufacture or sell vaccines directly; instead, it operates through six expert working groups (Regulatory Affairs, Pharmacovigilance, Supply Chain and Traceability, 3Rs alternative testing, Clinical Development, Manufacturing Sciences), the PSPT Consortium (established 2020 to replace animal-based pertussis testing), the Technical Collaborations Portal (for sharing member manufacturing capacity), and a Moodle-based e-learning platform including a novel VR training module for the Monocyte Activation Test developed with Istituto Superiore di Sanità and Lucerne University. Annual General Meetings (26th in Bali October 2025, 27th scheduled for Beijing September 2026) serve as the flagship convening events.

The alliance's economic value flows through its member manufacturers rather than its own balance sheet. Members supply vaccines to over 150 countries and accounted for more than 60% of global COVID-19 vaccine doses during the pandemic (over 9 billion doses cumulatively), with Bio Farma alone holding 3.5+ billion doses/year production capacity. Members support 19 of Gavi's 20 vaccine programs, with 12 supplied solely by DCVMN members, and rely on WHO prequalification, UNICEF Supply Division, and PAHO Revolving Fund as primary procurement channels. Revenue for the DCVMN secretariat itself derives from membership dues and corporate sponsorships (including Tofflon, Cytiva, Biozeen, GEA, WuXi Vaccines, Adjuvant Capital, and others), but is not publicly disclosed. Strategic leadership is provided by CEO Rajinder Suri and a rotating Board (Indonesia through Bio Farma chaired 2023-2025), with operational activity supported by a small 1-10 employee secretariat. Recent member regulatory milestones include WHO prequalification for FLU-M influenza and GreenSignal BCG vaccines, plus NMPA approvals for Cecolin 9 (HPV) and Rotasiro (hexavalent rotavirus).

Name

Developing Countries Vaccine Manufacturers Network

Legal name

DCVMN International

Website

https://dcvmn.org

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

DCVMN is a voluntary Geneva-based alliance of 48 vaccine manufacturers from 17 developing countries, coordinating regulatory harmonization, technology transfer, and training across all six WHO regions. Members supply over 150 countries and supported 19 of Gavi's 20 vaccine programs.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing Alliance

NAICS

Business Associations (813910), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Global Immunization & Vaccine Access Alliances (HLAJAKAK)

akta.pro secondary industries

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs (HLAJAHAK), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Vaccine manufacturing alliance
• Global health network
• Regulatory harmonization services
• Vaccine technology transfer
• Immunization capacity building

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&amp, D, Marketing or Sales, Others

Revenue model

1. Network Membership Dues: DCVMN is a voluntary alliance of vaccine manufacturers. Revenue appears to come from membership contributions and sponsorships to fund the secretariat operations, working groups, and educational programs.
2. Member Vaccine Sales: Member manufacturers supply vaccines to over 150 countries worldwide. The network facilitates these partnerships but does not directly generate revenue from vaccine sales.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

DCVMN is a voluntary public-health-driven alliance of 48 vaccine manufacturers from 17 developing countries, headquartered in Geneva, Switzerland. It facilitates regulatory harmonization, technology transfer, workforce training, and advocacy to expand equitable global access to high-quality vaccines. The alliance operates an e-learning platform, VR-based training tools, expert working groups, the PSPT research consortium, and an annual general meeting to strengthen members' manufacturing capacity and pandemic preparedness.

Product overview

DCVMN operates as a voluntary public health-driven alliance of vaccine manufacturers from developing countries. Rather than a unified product platform, DCVMN offers a portfolio of collaborative programs and services: its E-learning Platform (Moodle) and VR Training Modules provide innovative workforce development; the Technical Collaborations Portal enables members to share manufacturing capacities; the PSPT Consortium facilitates alternative testing methods research; six Expert Working Groups drive peer collaboration in regulatory affairs, pharmacovigilance, supply chain, 3Rs, and clinical development; and Annual General Meetings convene the global vaccine community. The COVID-19 Information Bank serves as a resource hub during health emergencies.

Differentiator

Problem solved

Functional benefit

Products and services

• E-learning Platform (Moodle)

Quantifiable outcome

• 60%+ of global COVID-19 vaccine production supplied by DCVMN members during the pandemic
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature5 records

Partnerships

14 partnerships are on record, tiered core and major.

• Bio Farma IndonesiacoreStrategic or Co-development Partner · 29 October 2025Bio Farma served as Chair of DCVMN for 2023-2025 period, hosting the 26th DCVMN AGM in Bali. Bio Farma achieved WHO Emergency Use Listing for nOPV2 vaccine in 2020, demonstrating developing-country manufacturers can meet international quality standards. The company supplies vaccines to over 150 countries with production capacity exceeding 3.5 billion doses per year.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO collaborates with DCVMN on regulatory harmonization, prequalification, Emergency Use Listing procedures, and pandemic preparedness. DCVMN members participate in WHO working groups and initiatives including the i-MCM-Net for medical countermeasures.
• Gavi, the Vaccine AlliancecoreStrategic or Co-development PartnerDCVMN members support 19 of Gavi's 20 programs, with 12 vaccines supplied solely by DCVMN members. Gavi's advance market commitment and financing mechanisms enable DCVMN manufacturers to supply affordable vaccines to developing countries.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development PartnerCEPI partners with DCVMN on pandemic preparedness, H5N1 vaccine readiness workshops, and manufacturing capacity strengthening. DCVMN CEO participates in CEPI-led initiatives for the 100 Days Mission.
• PATHmajorImplementation/ SI/ Consulting PartnerDCVMN and PATH collaborate on pharmacovigilance e-workshops, packaging technology workshops, and the CHAI Go-to-market toolbox for developing country manufacturers.
• Medicines Patent PoolmajorStrategic or Co-development PartnerThe Medicines Patent Pool implements WHO's C-TAP initiative. DCVMN member Medigen Vaccine Biologics Corp out-licensed COVID-19 vaccine technology to C-TAP/MMP, enabling technology transfer and staff training for broader vaccine availability.
• Istituto Superiore di Sanità (ISS), ItalymajorTechnology or IntegrationISS collaborated on the Pertussis Serological Potency Test (PSPT) project and the Monocyte Activation Test (MAT) VR training module development, providing scientific expertise for alternative vaccine testing methods.
• Intravacc, NetherlandsmajorTechnology or IntegrationIntravacc contributed to the PSPT project for pertussis vaccine testing alternatives, working with DCVMN members on coating antigen production and characterization.
• Lucerne University of Applied Sciences and Arts (HSLU)majorTechnology or IntegrationCollaborated with DCVMN and ISS to develop VR training tools for Monocyte Activation Test, providing hands-on laboratory experiences using virtual reality technology.
• Indian Council of Medical Research (ICMR)majorStrategic or Co-development PartnerICMR and CEPI co-organized the H5N1 Vaccine Readiness Workshop in New Delhi, bringing together DCVMN and industry stakeholders to assess India's R&D and manufacturing pathways for pandemic preparedness.
• Africa CDCcoreStrategic or Co-development PartnerAfrica CDC collaborates with DCVMN on workforce development, with DCVMN's Tech Transfer Training programs delivering programs with ~25% African participation, including an Africa-focused edition developed with Africa CDC.
• Hilleman LaboratoriesmajorStrategic or Co-development PartnerDCVMN developed Tech Transfer Training (train-the-trainers) programs with Hilleman Laboratories, with five programs delivered training 70+ professionals across developing countries.
• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)majorGTM or Marketing PartnerIFPMA representatives participate routinely in DCVMN Regulatory Working Group meetings. The groups collaborate on publications and joint proposals to WHO for regulatory harmonization.
• GS1majorTechnology or IntegrationGS1 standards for traceability and barcoding are promoted through the DCVMN Supply Chain Working Group, with pilot studies on primary and secondary packaging barcoding across six member companies.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Others

• WHO Prequalification Programme: WHO programme that qualifies vaccines for UN agency procurement. Functions as a regulatory gatekeeper that DCVMN members must work through; conceptually adjacent as a vaccine access enabler though structurally distinct.
• Serum Institute of India: World's largest vaccine manufacturer by doses and a DCVMN member peer in scale. Although a member rather than peer, Serum Institute represents the upper bound of developing-country vaccine manufacturing capability and is often compared with DCVMN's collective footprint.
• Gavi, the Vaccine Alliance: Public-private partnership funding immunization in lower-income countries. While not a peer organization, Gavi is the principal downstream customer/procurement channel for DCVMN members and shapes member revenue trajectories.
• CEPI (Coalition for Epidemic Preparedness Innovations): Global partnership financing vaccine development against epidemic threats. Functions as a partnership counterparty for DCVMN on pandemic preparedness rather than a direct competitor; collaborates via the 100 Days Mission and H5N1 readiness workshops.
• Bill & Melinda Gates Foundation: Major funder of global vaccine access, Gavi, and vaccine manufacturers in developing countries. Not a peer organization but a critical ecosystem stakeholder whose funding priorities shape DCVMN member opportunities.

Broad incumbents

• BIO (Biotechnology Innovation Organization): Large US-based biotech industry trade association. Comparable as a membership-driven industry advocacy organization representing companies in biopharmaceuticals and vaccines, though broader in scope (all biotech) and serving developed-market members primarily.
• PhRMA (Pharmaceutical Research and Manufacturers of America): US pharma industry association. Comparable as a national-level pharmaceutical industry alliance engaging regulators and policy makers, but PhRMA represents the largest multinational innovators rather than developing-country manufacturers.

Emerging players

• African Vaccine Manufacturing Initiative (AVMI): African-focused vaccine manufacturing advocacy network. Comparable as an emerging-market vaccine manufacturer alliance with a narrower geographic scope than DCVMN, focused exclusively on African capacity building.

Direct peers

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Global pharma industry association representing innovative biopharmaceutical companies and vaccine manufacturers. Most direct functional peer to DCVMN — both serve as industry conveners engaging WHO, but IFPMA represents multinational incumbents while DCVMN represents developing-country manufacturers.

Regional players

• Vaccines Europe: European vaccine industry group within EFPIA representing major European vaccine manufacturers. Comparable as a regional vaccine manufacturer alliance, but focused on Europe rather than developing countries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC6zDrb3vh9f4B6sDMT-aLXQ/featured
• LinkedInlinkedin.com/company/dcvmn

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Developing Countries Vaccine Manufacturers Network